133 related articles for article (PubMed ID: 9892684)
1. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting.
Sun X; Funk CD; Deng C; Sahu A; Lambris JD; Song WC
Proc Natl Acad Sci U S A; 1999 Jan; 96(2):628-33. PubMed ID: 9892684
[TBL] [Abstract][Full Text] [Related]
2. Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies.
Lin F; Fukuoka Y; Spicer A; Ohta R; Okada N; Harris CL; Emancipator SN; Medof ME
Immunology; 2001 Oct; 104(2):215-25. PubMed ID: 11683962
[TBL] [Abstract][Full Text] [Related]
3. Triple-fusion protein (TriFu): A potent, targeted, enzyme-like inhibitor of all three complement activation pathways.
Sonnentag SJ; Dopler A; Kleiner K; Garg BK; Mannes M; Späth N; Akilah A; Höchsmann B; Schrezenmeier H; Anliker M; Boyanapalli R; Huber-Lang M; Schmidt CQ
J Biol Chem; 2024 Apr; 300(4):105784. PubMed ID: 38401844
[TBL] [Abstract][Full Text] [Related]
4. What is the role of complement in bystander hemolysis? Old concept, new insights.
Evangelidis P; Evangelidis N; Vlachaki E; Gavriilaki E
Expert Rev Hematol; 2024; 17(4-5):107-116. PubMed ID: 38708453
[TBL] [Abstract][Full Text] [Related]
5. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation.
Song H; He C; Knaak C; Guthridge JM; Holers VM; Tomlinson S
J Clin Invest; 2003 Jun; 111(12):1875-85. PubMed ID: 12813023
[TBL] [Abstract][Full Text] [Related]
6. Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55.
Gifford G; Vu VP; Banda NK; Holers VM; Wang G; Groman EV; Backos D; Scheinman R; Moghimi SM; Simberg D
J Control Release; 2019 May; 302():181-189. PubMed ID: 30974134
[TBL] [Abstract][Full Text] [Related]
7. Sodium butyrate enhances complement-mediated cell injury via down-regulation of decay-accelerating factor expression in colonic cancer cells.
Andoh A; Shimada M; Araki Y; Fujiyama Y; Bamba T
Cancer Immunol Immunother; 2002 Feb; 50(12):663-72. PubMed ID: 11862418
[TBL] [Abstract][Full Text] [Related]
8. Complement decay accelerating factor (DAF)/CD55 in cancer.
Spendlove I; Ramage JM; Bradley R; Harris C; Durrant LG
Cancer Immunol Immunother; 2006 Aug; 55(8):987-95. PubMed ID: 16485129
[TBL] [Abstract][Full Text] [Related]
9. Hemopexin Modulates Expression of Complement Regulatory Proteins in Rat Glomeruli.
Detsika MG; Lianos EA
Curr Issues Mol Biol; 2021 Sep; 43(2):1081-1089. PubMed ID: 34563046
[TBL] [Abstract][Full Text] [Related]
10. CD55 in cancer: Complementing functions in a non-canonical manner.
Bharti R; Dey G; Lin F; Lathia J; Reizes O
Cancer Lett; 2022 Dec; 551():215935. PubMed ID: 36216147
[TBL] [Abstract][Full Text] [Related]
11. A nanobody-based complement inhibitor targeting complement component 2 reduces hemolysis in a complement humanized mouse model of autoimmune hemolytic anemia.
Chen JY; Zhang L; Luo L; Yang M; Chen Y; Lin F
Clin Immunol; 2023 Aug; 253():109678. PubMed ID: 37315680
[TBL] [Abstract][Full Text] [Related]
12. Pozelimab, a human monoclonal immunoglobulin for the treatment of CHAPLE disease.
Kaur M; Misra S
J Basic Clin Physiol Pharmacol; 2024 Apr; ():. PubMed ID: 38598858
[TBL] [Abstract][Full Text] [Related]
13. Development of a C3 Humanized Rat as a New Model for Evaluating Novel C3 Inhibitors.
Chen JY; Zhang L; Yang M; Hughes ED; Freeman ZT; Saunders TL; Lin F
J Innate Immun; 2024; 16(1):56-65. PubMed ID: 38035563
[TBL] [Abstract][Full Text] [Related]
14. Surviving without oxygen involves major tissue specific changes in the proteome of crucian carp (
Johansen A; Thiede B; Anonsen JH; Nilsson GE
PeerJ; 2023; 11():e14890. PubMed ID: 36915662
[TBL] [Abstract][Full Text] [Related]
15. The immunobiology and clinical use of genetically engineered porcine hearts for cardiac xenotransplantation.
Goerlich CE; Singh AK; Griffith BP; Mohiuddin MM
Nat Cardiovasc Res; 2022 Aug; 1(8):715-726. PubMed ID: 36895262
[TBL] [Abstract][Full Text] [Related]
16. Expression dynamics of Crry at the implantation sites in normal pregnancy and response against miscarriage induction.
Kuniyoshi N; Hanada S; Ando R; Yustinasari LR; Kuratomi M; Kagawa S; Imai H; Kusakabe KT
J Vet Med Sci; 2023 Jan; 85(1):92-98. PubMed ID: 36450590
[TBL] [Abstract][Full Text] [Related]
17. Contribution of animal models to the mechanistic understanding of Alternative Pathway and Amplification Loop (AP/AL)-driven Complement-mediated Diseases.
Gibson BG; Cox TE; Marchbank KJ
Immunol Rev; 2023 Jan; 313(1):194-216. PubMed ID: 36203396
[TBL] [Abstract][Full Text] [Related]
18. CD55 Facilitates Immune Evasion by Borrelia crocidurae, an Agent of Relapsing Fever.
Arora G; Lynn GE; Tang X; Rosen CE; Hoornstra D; Sajid A; Hovius JW; Palm NW; Ring AM; Fikrig E
mBio; 2022 Oct; 13(5):e0116122. PubMed ID: 36036625
[TBL] [Abstract][Full Text] [Related]
19. Insights Into the Emergence of Paroxysmal Nocturnal Hemoglobinuria.
Colden MA; Kumar S; Munkhbileg B; Babushok DV
Front Immunol; 2021; 12():830172. PubMed ID: 35154088
[TBL] [Abstract][Full Text] [Related]
20. Revisiting the Mechanisms of Immune Evasion Employed by Human Parasites.
Chulanetra M; Chaicumpa W
Front Cell Infect Microbiol; 2021; 11():702125. PubMed ID: 34395313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
